RxDoctor Payments Data

Sandy Jackson

Family · Cuba, NYNPI 1043671530

Payments from drug & device makers

$9,927in general payments, 2019–2025

Across 586 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$1K
  • GSK$1K
  • Lilly USA, LLC$973
  • AbbVie$825
  • Amgen$558
  • plus $4K from 32 others

What the payments were for

  • Food & beverage$9,84399%
  • Education$841%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,927 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$61,099
Medicare patients
181
Services billed
1,007

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide170$223,617
JardianceEmpagliflozin124$124,673
MounjaroTirzepatide76$104,162
EliquisApixaban135$95,731
FarxigaDapagliflozin Propanediol75$86,769
XareltoRivaroxaban43$58,513
RybelsusSemaglutide32$56,874
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$53,206
Breztri AerosphereBudesonide/Glycopyr/Formoterol52$42,888
RexultiBrexpiprazole14$26,549
ProliaDenosumab11$19,939
MyrbetriqMirabegron19$18,934
LinzessLinaclotide23$18,318
Spiriva RespimatTiotropium Bromide29$16,844
VraylarCariprazine Hcl13$16,549

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,423$280,491202 claims
Boehringer IngelheimJardiance, Spiriva Respimat$249$141,517153 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,544$129,658127 claims
Lilly USA, LLCMounjaro$973$104,16276 claims
PfizerEliquis, Dilantin$286$97,969150 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$1,060$69,494106 claims
Johnson & JohnsonXarelto$172$58,51343 claims
AbbVieLinzess, Vraylar$825$34,86736 claims
Otsuka America Pharmaceutical, Inc.Rexulti$168$26,54914 claims
AmgenProlia$558$19,93911 claims
Astellas Pharma US IncMyrbetriq$141$18,93419 claims
MerckJanuvia$405$11,28211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in Cuba

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →